Linked Life Data

6135076

Source:http://linkedlifedata.com/resource/pubmed/id/6135076

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8344
pubmed:dateCreated
1983-8-26
pubmed:abstractText
In a group of thirty patients with tumour-induced hypercalcaemia the effects of volume repletion and intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) were examined. Volume repletion was only partially effective in lowering serum calcium and raising glomerular filtration rate and it increased the tendency towards hypomagnesaemia. In twenty-nine of the patients serum calcium, serum magnesium, and glomerular filtration rate were rapidly restored to normal by intravenous APD, in doses of 1.75-30 mg/day. Tubular reabsorption of phosphate was lower than normal in five of nine patients in whom it was studied and remained unchanged despite correction of hypovolaemia and serum and urine calcium levels or changes in parathyroid hormone. These findings suggested that tumours may produce a phosphate-lowering factor. The improvement in clinical condition with volume repletion depends on its ability to adjust calcium excretion to the abnormal production of calcium from bone. APD, in contrast, returns pathological bone destruction to normal without any undesirable side-effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0140-6736
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
239-43
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial, Research Support, Non-U.S. Gov't